Plain-English fact sheet
Tirzepatide
Also known as Mounjaro, Zepbound
Tirzepatide is a peptide-based medicine with strong human evidence for specific FDA-approved uses, including type 2 diabetes and chronic weight management.
Quick answer
Tirzepatide is FDA approved in specific prescription products and populations. Zepbound also has an FDA-approved indication for moderate-to-severe obstructive sleep apnea in adults with obesity.
By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.
What is Tirzepatide?
Tirzepatide is a manufactured medicine that activates two receptors involved in metabolic signaling: GIP and GLP-1.
Mounjaro and Zepbound contain the same active ingredient but have distinct FDA-labeled uses.
Why are people interested in it?
Interest centers on blood-sugar control, body-weight outcomes, and the newer obstructive-sleep-apnea indication.
It is also being studied for cardiovascular, kidney, and liver outcomes.
Current regulatory status
Tirzepatide products are FDA approved for specific uses, including type 2 diabetes, chronic weight management, and—under the Zepbound label—moderate-to-severe obstructive sleep apnea in adults with obesity.
What is it approved for?
- Improving blood sugar control in specified people with type 2 diabetes
- Chronic weight management in specified adults
- Moderate-to-severe obstructive sleep apnea in adults with obesity under the Zepbound label
What is it being studied for?
Investigational areas
- Additional cardiovascular, kidney, and liver outcomes
- Other uses not listed in a current product label
Evidence snapshot
Large randomized trials support approved indications. Results cannot be assumed to apply to unstudied populations, products, or claims.
Potential benefits being researched
- Trials supporting approved labels found benefits in their specified metabolic and sleep-apnea outcomes.
- Additional outcome studies may clarify where benefits extend beyond current labels.
Potential does not mean proven. Study design, population, endpoint, and regulatory review matter.
Known or possible risks
- Common effects include nausea, diarrhea, vomiting, constipation, abdominal discomfort, and other gastrointestinal symptoms.
- Current labeling includes a boxed warning about thyroid C-cell tumors in rats and important contraindications.
- Other labeled concerns include pancreatitis, gallbladder problems, kidney injury, hypoglycemia with certain medicines, and aspiration risk around anesthesia or deep sedation.
What we still do not know
- Outcomes for uses and populations not yet studied in large trials
- Very long-term outcomes across increasingly broad populations
- Whether every ongoing outcome trial will confirm early signals
- Quality and safety of products marketed outside approved supply chains
Plain-English takeaway
Tirzepatide has strong evidence for specific approved uses, but brand, indication, eligibility, contraindications, and clinical oversight all matter.
Research and reference links
Use these primary and reputable sources to verify status and read beyond this summary. Trial registries may list studies without proving a benefit.
- 1FDA Drugs@FDA search: tirzepatide
Official FDA approval records, labels, and regulatory history.
- 2FDA: first medication approved for obstructive sleep apnea
FDA announcement of the Zepbound obstructive-sleep-apnea indication.
- 3ClinicalTrials.gov studies: tirzepatide
Current and completed registered clinical studies.
- 4PubMed research: tirzepatide randomized trial
Peer-reviewed literature indexed by the National Library of Medicine.